<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tatjana T. Makovski</style></author><author><style face="normal" font="default" size="100%">Jinane Ghattas</style></author><author><style face="normal" font="default" size="100%">Stéphanie Monnier-Besnard</style></author><author><style face="normal" font="default" size="100%">Lisa Cavillot</style></author><author><style face="normal" font="default" size="100%">Monika Ambrozova</style></author><author><style face="normal" font="default" size="100%">Barbora Vasinova</style></author><author><style face="normal" font="default" size="100%">Rodrigo Feteira-Santos</style></author><author><style face="normal" font="default" size="100%">Peter Bezzegh</style></author><author><style face="normal" font="default" size="100%">Felipe Ponce Bollmann</style></author><author><style face="normal" font="default" size="100%">James Cottam</style></author><author><style face="normal" font="default" size="100%">Romana Haneef</style></author><author><style face="normal" font="default" size="100%">Brecht Devleesschauwer</style></author><author><style face="normal" font="default" size="100%">Niko Speybroeck</style></author><author><style face="normal" font="default" size="100%">Paulo Jorge Nogueira</style></author><author><style face="normal" font="default" size="100%">Maria João Forjaz</style></author><author><style face="normal" font="default" size="100%">Joel Coste</style></author><author><style face="normal" font="default" size="100%">Laure Carcaillon-Bentata</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Multimorbidity and frailty are associated with poorer SARS-CoV-2-related outcomes: systematic review of population-based studies</style></title><secondary-title><style face="normal" font="default" size="100%">Aging Clinical and Experimental Research</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">frailty</style></keyword><keyword><style  face="normal" font="default" size="100%">multimorbidity</style></keyword><keyword><style  face="normal" font="default" size="100%">Multiple chronic conditions</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan-12-2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">36</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Background&lt;/p&gt;

&lt;p&gt;Estimating the risks and impacts of COVID-19 for different health groups at the population level is essential for orienting public health measures. Adopting a population-based approach, we conducted a systematic review to explore: (1) the etiological role of multimorbidity and frailty in developing SARS-CoV-2 infection and COVID-19-related short-term outcomes; and (2) the prognostic role of multimorbidity and frailty in developing short- and long-term outcomes. This review presents the state of the evidence in the early years of the pandemic. It was conducted within the European Union Horizon 2020 program (No: 101018317); Prospero registration: CRD42021249444.&lt;/p&gt;

&lt;p&gt;Methods&lt;/p&gt;

&lt;p&gt;PubMed, Embase, World Health Organisation COVID-19 Global literature on coronavirus disease, and PsycINFO were searched between January 2020 and 7 April 2021 for multimorbidity and 1 February 2022 for frailty. Quantitative peer-reviewed studies published in English with population-representative samples and validated multimorbidity and frailty tools were considered.&lt;/p&gt;

&lt;p&gt;Results&lt;/p&gt;

&lt;p&gt;Overall, 9,701 records were screened by title/abstract and 267 with full text. Finally, 14 studies were retained for multimorbidity (etiological role, n = 2; prognostic, n = 13) and 5 for frailty (etiological role, n = 2; prognostic, n = 4). Only short-term outcomes, mainly mortality, were identified. An elevated likelihood of poorer outcomes was associated with an increasing number of diseases, a higher Charlson Comorbidity Index, different disease combinations, and an increasing frailty level.&lt;/p&gt;

&lt;p&gt;Discussion&lt;/p&gt;

&lt;p&gt;Future studies, which include the effects of recent virus variants, repeated exposure and vaccination, will be useful for comparing the possible evolution of the associations observed in the earlier waves.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record></records></xml>